Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
25 févr. 2022 02h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma If approved by the European Medicines Agency,...
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
26 janv. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanomaKIMMTRAK is the first and only FDA approved therapy for the treatment of...
Immunocore to present at upcoming investor conferences
27 mai 2021 16h30 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 27 May 2021) Immunocore (Nasdaq: IMCR), a late-stage...